Red eyes are one of the most common eye concerns, and for many people, Visine is the first solution that comes to mind.

The drops work fast, making eyes look whiter within minutes. But what if that quick fix is actually making redness worse over time?

In a recent educational YouTube video, Dr. C., founder of Eye Drop Shop and a double board-certified optometrist, explains why traditional redness-relief drops can lead to rebound redness, how products like Lumify differ, and what you can do to address the real cause of red eyes.

Before you reach for another bottle of Visine, here's what you should know about eye redness, the risks of overusing redness-relief drops, and when newer alternatives may be a better option.

Red Eyes Are a Symptom, Not a Diagnosis

One of the biggest misconceptions about red eyes is that redness itself is the condition.

In reality, red eyes can be caused by a wide range of underlying issues, including:

• Dry eye disease
• Blepharitis (eyelid inflammation)
• Allergies

When redness appears, the tiny blood vessels on the surface of the eye become enlarged and more visible. This is often the body's response to irritation, inflammation, or tear film instability.

Instead of asking, "How do I get rid of red eyes?" a better question is, "Why are my eyes red?"

Treating the root cause often leads to healthier, more comfortable eyes and a natural reduction in redness over time.

How Visine Actually Works

Traditional redness-relief drops such as Visine contain an ingredient called tetrahydrozoline, an alpha-adrenergic agonist.

Tetrahydrozoline works by constricting blood vessels on the surface of the eye. When these vessels become smaller, less redness is visible, creating the appearance of clearer, whiter eyes (Abelson et al., 2018).

The effect can be dramatic and nearly immediate.

However, while your eyes may look whiter, the underlying cause of the redness remains.

The Problem With Rebound Redness

One of the biggest concerns with frequent use of vasoconstrictor eye drops like Visine is a phenomenon known as rebound redness.

Repeated constriction of blood vessels can lead to a cycle where the vessels dilate again once the medication wears off. Over time, users may notice that their eyes look redder between applications and feel increasingly dependent on the drops.

This cycle encourages more frequent use, which can further perpetuate the problem (Abelson et al., 2018).

Many eye care professionals advise against routine use of traditional redness-relief drops because of this risk.

While occasional use may not cause issues for everyone, chronic use can become frustrating and difficult to break.

Why Lumify Is Different

Not all redness-relief drops work the same way.

Lumify contains brimonidine tartrate 0.025%, a selective alpha-2 adrenergic receptor agonist.

A randomized clinical trial found that low-dose brimonidine tartrate significantly reduced ocular redness and was associated with a favorable safety profile, with minimal evidence of tachyphylaxis or rebound redness (McLaurin et al., 2018).

This is why many eye care professionals view Lumify differently than products containing tetrahydrozoline or naphazoline.

Can You Use Lumify Every Day?

Even though Lumify has a better safety profile, it is still important to remember that white eyes do not necessarily mean healthy eyes.

Lumify can be a useful option for:

• Special events
• Weddings
• Professional photos
  

However, if you find yourself reaching for redness-relief drops every day, that may be a sign that an underlying condition needs attention.

Persistent redness often points to dry eye disease, meibomian gland dysfunction, allergies, or chronic inflammation that deserves proper evaluation and treatment.

The Better Long-Term Solution: Treat the Cause

If your goal is consistently comfortable, healthy-looking eyes, focusing on ocular surface health is usually the better strategy.

Research consistently shows that managing dry eye disease and ocular surface inflammation can improve both symptoms and redness over time (Craig et al., 2017).

Some foundational strategies include:

1. Use Preservative-Free Artificial Tears

Artificial tears help stabilize the tear film and reduce irritation.

Preservative-free formulations are often preferred for frequent use because preservatives may worsen ocular surface irritation in susceptible individuals (Jones et al., 2017).

2. Support Your Tear Film With Omega-3s

Omega-3 fatty acids may help improve meibomian gland function and support a healthier tear film in some patients with dry eye disease (Downie et al., 2019).

3. Maintain Good Eyelid Hygiene

Blepharitis and meibomian gland dysfunction are major contributors to redness and irritation.

Regular eyelid cleansing can help remove debris, bacteria, and inflammatory material that accumulate along the lash line. Products such as I-LID ’N LASH® Plus, WE LOVE EYES Calm Hypochlorous Eyelid Spray, and WE LOVE EYES Eyelid Foaming Cleanser can support a consistent eyelid hygiene routine by helping gently cleanse the eyelid margin and maintain a healthier ocular surface.

4. Take Regular Screen Breaks

Digital device use significantly reduces blink frequency, which can accelerate tear evaporation and increase redness.

Following the 20-20-20 rule can help reduce digital eye strain and dry eye symptoms.

5. Schedule an Eye Examination

If redness is persistent, recurring, or accompanied by pain, discharge, light sensitivity, or changes in vision, a comprehensive eye examination is essential to determine the underlying cause.

Already Using Visine Every Day?

If you've been relying on Visine or other redness-relief drops daily, there is no need to panic.

Many patients successfully reduce their dependence on these products with guidance from an eye care professional.

The best approach is to identify the underlying cause of the redness and gradually transition toward therapies that support long-term eye health.

You do not have to navigate that process alone.

The Takeaway

Red eyes are often your body's way of signaling that something is irritating or inflaming the surface of your eyes.

While Visine may temporarily hide the redness, it does not solve the underlying problem and may contribute to rebound redness when used regularly.

Lumify represents a newer option with a lower risk of rebound redness and may be appropriate for occasional use before special events.

For long-term results, the real solution is addressing the root cause. Whether that means managing dry eye disease, improving eyelid hygiene, treating allergies, or supporting your tear film, healthier eyes naturally look whiter and feel better.

Your future self will thank you for treating the cause instead of simply covering up the symptom.

References

Abelson, M. B., Butrus, S. I., Weston, J. H., & Guerin, M. M. (2018). Ocular pharmacology and therapeutic use of vasoconstrictors for conjunctival hyperemia. Clinical Ophthalmology, 12, 2411-2421. https://doi.org/10.2147/OPTH.S174540

Craig, J. P., Nichols, K. K., Akpek, E. K., Caffery, B., Dua, H. S., Joo, C. K., Liu, Z., Nelson, J. D., Nichols, J. J., Tsubota, K., & Stapleton, F. (2017). TFOS DEWS II definition and classification report. The Ocular Surface, 15(3), 276-283. https://doi.org/10.1016/j.jtos.2017.05.008

Downie, L. E., Ng, S. M., Lindsley, K. B., Akpek, E. K., & Chauhan, S. K. (2019). Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease. Cochrane Database of Systematic Reviews, 12, CD011016. https://doi.org/10.1002/14651858.CD011016.pub2

Jones, L., Downie, L. E., Korb, D., Benitez-Del-Castillo, J. M., Dana, R., Deng, S. X., Dong, P. N., Geerling, G., Hida, R. Y., Liu, Y., Seo, K. Y., Tauber, J., Wakamatsu, T. H., Xu, J., Wolffsohn, J. S., & Craig, J. P. (2017). TFOS DEWS II management and therapy report. The Ocular Surface, 15(3), 575-628. https://doi.org/10.1016/j.jtos.2017.05.006

McLaurin, E. B., Shedden, A. C., & Torkildsen, G. L. (2018). Brimonidine tartrate ophthalmic solution 0.025% for reduction of ocular redness: A randomized clinical trial. Optometry and Vision Science, 95(3), 183–189. https://pubmed.ncbi.nlm.nih.gov/29461408/